

**Contact:**

Anthony Recupero  
Vice President Business Development  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

**MaxCyte To Be Featured at BioPartnering Europe Conference**

**Gaithersburg, MD, October 2, 2006** – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale cell loading systems for cellular therapy, including personalized cellular approaches, will be presenting at the BioPartnering Europe Conference in London, UK, Queen Elizabeth II Conference Centre, on Tuesday, October 10, 2006, Open House Presentations, Group 4 from 1:30 PM to 4:00 PM.

MaxCyte will provide a brief corporate overview and discuss the company's preclinical and clinical product candidates, partnering activities, and enabling technology for therapeutic development and biotherapeutic manufacturing.

**About MaxCyte**

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary *ex vivo* cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility, which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers: one in Phase I/II clinical trials for treatment of chronic lymphocytic leukemia (CLL) and several preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

**For more information, visit <http://www.maxcyte.com>.**

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###